FDA
-
-
-
-
-
-
-
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Quoin Pharmaceuticals receives FDA fast track designation for QRX003
-
-
-
-
-
-
-
Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results
-
-
-
-
-
-
-
Quoin Pharmaceuticals Ltd (QNRX) Granted FDA Rare Pediatric Disease Designation for QRX003
-
-
-
-
-
-
-
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
-
-
-
-
-
-
-
Quoin Pharmaceuticals (QNRX) Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
-
-
-
-
-
-
-
Quoin Pharmaceuticals (QNRX) Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

